🚀 VC round data is live in beta, check it out!
Xilio Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Xilio Therapeutics and similar public comparables like Ascelia Pharma, Veru, Jasper Therapeutics, Radiopharm Theranostics and more.
Xilio Therapeutics Overview
About Xilio Therapeutics
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
Founded
2020
HQ
Employees
64
Website
Sectors
Financials (FY)
Market Cap
$40M
Xilio Therapeutics Financials
Xilio Therapeutics reported last fiscal year revenue of $6M and negative EBITDA of ($58M).
In the same fiscal year, Xilio Therapeutics generated ($58M) in EBITDA losses and had net loss of ($58M).
Revenue (LTM)
Xilio Therapeutics P&L
In the most recent fiscal year, Xilio Therapeutics reported revenue of $6M and EBITDA of ($58M).
Xilio Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $6M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($58M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (914%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (940%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($58M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (918%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Xilio Therapeutics Stock Performance
Xilio Therapeutics has current market cap of $40M.
Market Cap Evolution
Xilio Therapeutics' stock price is $0.54.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $40M | 0.0% | XXX | XXX | XXX | $-0.79 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialXilio Therapeutics Valuation Multiples
Xilio Therapeutics trades at (8.9x) EV/Revenue multiple, and 1.0x EV/EBITDA.
EV / Revenue (LTM)
Xilio Therapeutics Financial Valuation Multiples
As of March 18, 2026, Xilio Therapeutics has market cap of $40M.
Equity research analysts estimate Xilio Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xilio Therapeutics has a P/E ratio of (0.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $40M | XXX | $40M | XXX | XXX | XXX |
| EV (current) | ($57M) | XXX | ($57M) | XXX | XXX | XXX |
| EV/Revenue | — | XXX | (8.9x) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 0.9x | XXX | XXX | XXX |
| P/E | — | XXX | (0.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 3.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Xilio Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Xilio Therapeutics Margins & Growth Rates
Xilio Therapeutics' revenue in the last fiscal year grew by —.
Xilio Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Margin | — | XXX | (914%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (25%) | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 391% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 650% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1040% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Xilio Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ascelia Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Veru | XXX | XXX | XXX | XXX | XXX | XXX |
| Jasper Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Radiopharm Theranostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Atara Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xilio Therapeutics M&A Activity
Xilio Therapeutics acquired XXX companies to date.
Last acquisition by Xilio Therapeutics was on XXXXXXXX, XXXXX. Xilio Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Xilio Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialXilio Therapeutics Investment Activity
Xilio Therapeutics invested in XXX companies to date.
Xilio Therapeutics made its latest investment on XXXXXXXX, XXXXX. Xilio Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Xilio Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Xilio Therapeutics
| When was Xilio Therapeutics founded? | Xilio Therapeutics was founded in 2020. |
| Where is Xilio Therapeutics headquartered? | Xilio Therapeutics is headquartered in United States. |
| How many employees does Xilio Therapeutics have? | As of today, Xilio Therapeutics has over 64 employees. |
| Who is the CEO of Xilio Therapeutics? | Xilio Therapeutics' CEO is Rene Russo. |
| Is Xilio Therapeutics publicly listed? | Yes, Xilio Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Xilio Therapeutics? | Xilio Therapeutics trades under XLO ticker. |
| When did Xilio Therapeutics go public? | Xilio Therapeutics went public in 2021. |
| Who are competitors of Xilio Therapeutics? | Xilio Therapeutics main competitors are Ascelia Pharma, Veru, Jasper Therapeutics, Radiopharm Theranostics. |
| What is the current market cap of Xilio Therapeutics? | Xilio Therapeutics' current market cap is $40M. |
| What is the current revenue of Xilio Therapeutics? | Xilio Therapeutics' last fiscal year revenue is $6M. |
| What is the current EV/Revenue multiple of Xilio Therapeutics? | Current revenue multiple of Xilio Therapeutics is (8.9x). |
| Is Xilio Therapeutics profitable? | No, Xilio Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.